vs
AVANOS MEDICAL, INC.（AVNS）与Enovis CORP（ENOV）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是AVANOS MEDICAL, INC.的3.0倍（$548.9M vs $180.9M）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -104.1%，领先103.3%）。AVANOS MEDICAL, INC.同比增速更快（0.7% vs -2.2%）。Enovis CORP自由现金流更多（$29.1M vs $21.3M）。过去两年Enovis CORP的营收复合增速更高（9.8% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
AVNS vs ENOV — 直观对比
营收规模更大
ENOV
是对方的3.0倍
$180.9M
营收增速更快
AVNS
高出2.9%
-2.2%
净利率更高
AVNS
高出103.3%
-104.1%
自由现金流更多
ENOV
多$7.8M
$21.3M
两年增速更快
ENOV
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $548.9M |
| 净利润 | $-1.3M | $-571.1M |
| 毛利率 | 47.5% | 59.9% |
| 营业利润率 | 1.4% | -101.7% |
| 净利率 | -0.7% | -104.1% |
| 营收同比 | 0.7% | -2.2% |
| 净利润同比 | 99.7% | 18.8% |
| 每股收益（稀释后） | $-0.02 | $-9.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSENOV
| Q4 25 | $180.9M | $548.9M | ||
| Q3 25 | $177.8M | $564.5M | ||
| Q2 25 | $175.0M | $558.8M | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | $561.0M | ||
| Q3 24 | $170.4M | $505.2M | ||
| Q2 24 | $171.7M | $525.2M | ||
| Q1 24 | $166.1M | $516.3M |
净利润AVNSENOV
| Q4 25 | $-1.3M | $-571.1M | ||
| Q3 25 | $-1.4M | $-36.7M | ||
| Q2 25 | $-76.8M | $-56.0M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | $-703.2M | ||
| Q3 24 | $4.3M | $-31.5M | ||
| Q2 24 | $1.8M | $-18.6M | ||
| Q1 24 | $-900.0K | $-72.0M |
毛利率AVNSENOV
| Q4 25 | 47.5% | 59.9% | ||
| Q3 25 | 48.4% | 59.3% | ||
| Q2 25 | 52.6% | 59.5% | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | 54.8% | ||
| Q3 24 | 54.5% | 56.7% | ||
| Q2 24 | 55.7% | 55.0% | ||
| Q1 24 | 57.1% | 57.7% |
营业利润率AVNSENOV
| Q4 25 | 1.4% | -101.7% | ||
| Q3 25 | 0.1% | -3.0% | ||
| Q2 25 | -42.6% | -8.4% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | -118.5% | ||
| Q3 24 | 7.0% | -6.3% | ||
| Q2 24 | 3.7% | -8.4% | ||
| Q1 24 | 2.4% | -6.8% |
净利率AVNSENOV
| Q4 25 | -0.7% | -104.1% | ||
| Q3 25 | -0.8% | -6.5% | ||
| Q2 25 | -43.9% | -10.0% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | -125.4% | ||
| Q3 24 | 2.5% | -6.2% | ||
| Q2 24 | 1.0% | -3.5% | ||
| Q1 24 | -0.5% | -13.9% |
每股收益（稀释后）AVNSENOV
| Q4 25 | $-0.02 | $-9.99 | ||
| Q3 25 | $-0.03 | $-0.64 | ||
| Q2 25 | $-1.66 | $-0.98 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | $-12.69 | ||
| Q3 24 | $0.09 | $-0.58 | ||
| Q2 24 | $0.04 | $-0.34 | ||
| Q1 24 | $-0.02 | $-1.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $33.6M |
| 总债务越低越好 | $90.3M | $1.4B |
| 股东权益账面价值 | $778.2M | $2.0B |
| 总资产 | $1.1B | $4.4B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资AVNSENOV
| Q4 25 | $89.8M | $33.6M | ||
| Q3 25 | $70.5M | $44.1M | ||
| Q2 25 | $90.3M | $38.5M | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | $48.2M | ||
| Q3 24 | $89.0M | $35.4M | ||
| Q2 24 | $92.2M | $35.0M | ||
| Q1 24 | $75.8M | $66.3M |
总债务AVNSENOV
| Q4 25 | $90.3M | $1.4B | ||
| Q3 25 | $93.4M | $1.4B | ||
| Q2 25 | $95.7M | $1.4B | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $1.3B | ||
| Q3 24 | $152.6M | $1.3B | ||
| Q2 24 | $164.9M | $1.3B | ||
| Q1 24 | $167.2M | $1.3B |
股东权益AVNSENOV
| Q4 25 | $778.2M | $2.0B | ||
| Q3 25 | $778.0M | $2.6B | ||
| Q2 25 | $776.3M | $2.6B | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | $2.6B | ||
| Q3 24 | $1.2B | $3.3B | ||
| Q2 24 | $1.2B | $3.3B | ||
| Q1 24 | $1.2B | $3.3B |
总资产AVNSENOV
| Q4 25 | $1.1B | $4.4B | ||
| Q3 25 | $1.1B | $5.0B | ||
| Q2 25 | $1.0B | $4.9B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $4.7B | ||
| Q3 24 | $1.7B | $5.6B | ||
| Q2 24 | $1.7B | $5.4B | ||
| Q1 24 | $1.7B | $5.5B |
负债/权益比AVNSENOV
| Q4 25 | 0.12× | 0.67× | ||
| Q3 25 | 0.12× | 0.54× | ||
| Q2 25 | 0.12× | 0.53× | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 0.52× | ||
| Q3 24 | 0.12× | 0.40× | ||
| Q2 24 | 0.13× | 0.41× | ||
| Q1 24 | 0.14× | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $82.6M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $29.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 5.3% |
| 资本支出强度资本支出/营收 | 3.8% | 9.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $22.8M |
8季度趋势，按日历期对齐
经营现金流AVNSENOV
| Q4 25 | $28.2M | $82.6M | ||
| Q3 25 | $14.0M | $47.8M | ||
| Q2 25 | $6.8M | $-1.6M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $88.3M | ||
| Q3 24 | $23.0M | $53.6M | ||
| Q2 24 | $27.8M | $7.8M | ||
| Q1 24 | $-8.0M | $-36.2M |
自由现金流AVNSENOV
| Q4 25 | $21.3M | $29.1M | ||
| Q3 25 | $7.0M | $3.4M | ||
| Q2 25 | $-4.2M | $-44.9M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $35.1M | ||
| Q3 24 | $20.0M | $2.4M | ||
| Q2 24 | $21.9M | $-31.6M | ||
| Q1 24 | $-12.1M | $-73.1M |
自由现金流率AVNSENOV
| Q4 25 | 11.8% | 5.3% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | -2.4% | -8.0% | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | 6.3% | ||
| Q3 24 | 11.7% | 0.5% | ||
| Q2 24 | 12.8% | -6.0% | ||
| Q1 24 | -7.3% | -14.2% |
资本支出强度AVNSENOV
| Q4 25 | 3.8% | 9.7% | ||
| Q3 25 | 3.9% | 7.9% | ||
| Q2 25 | 6.3% | 7.7% | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | 9.5% | ||
| Q3 24 | 1.8% | 10.1% | ||
| Q2 24 | 3.4% | 7.5% | ||
| Q1 24 | 2.5% | 7.2% |
现金转化率AVNSENOV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
